First line chemotherapy for advanced ovarian cancer in 2000: Standards and questions;La chimiotherapie de premiere ligne du cancer evolue de l'ovaire en 2000: Principes et questions

Bulletin du Cancer

Volumn 87, Issue 2, 2000, Pages 189-199

  Cure, Hervé ^a   Dauplat, Jacques ^a   Chollet, Philippe ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Chemotherapy; Ovarian cancer

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MELPHALAN; OXALIPLATIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; OVARY CANCER; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; META ANALYSIS; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; META-ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0034132597     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. 1. Smith JP, Rutledge F, Wharton JT. Chemotherapy of ovarian cancer: new approachs to treatment. Cancer 1972 ; 30 : 1565-71.
2. 2. Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, et al. Advanced ovarian adenocarcinoma : a prospective clinical trial of Melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978 ; 299 : 1261-6.
3. 3. Anonymous. Chemotherapy in advanced ovarian cancer : an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. Br Med J 1991 ; 303 : 884-93.
4. 4. Anonymous. Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin. Cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45 : 115-7.
5. 5. Neijt JP, ten Bokkel Huinink WW, Van de Burg MEL, Van Oosterom AT, Willemse PHB, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987 ; 5 : 1157-68.
6. 6. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma : a Gynecology Oncology Group Study. J Clin Oncol 1989 ; 7 : 457-65.
7. 7. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of randomized trial of two doses of cisplatinc for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996 ; 14 (7) : 2113-9.
8. 8. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stade IV ovarian cancer. N Engl J Med 1996 ; 334 : 1-6.
9. 9. Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel (P-T) the standard in first line treatment of advanced ovarian canter (OvCa)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 1997 ; 1258a.
10. 10. Muggia FM, Braly PS, Brady MF, Sutton G, Copeland LJ, Lentz SL, et al. Phase III of cisplatin (P) or pacliraxel (T), versus their combination in suboptimal srage III and IV epithelial ovarian cancer (EOC) : Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 1997 ; 16 : abstract n° 1257a.
11. 11. Vermerken JB, ten Bokkel Huinink WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, et al. Carboplatin versus cisplatin. Ann Oncol 1993 ; 4 (suppl. 4) : S41-8.
12. 12. Belpomme D, Bugat R, Rives M, Pinon G, Roullet B, Facchini T, et al. Carboplarin versus cisplatin in association with cyclophosphamide and doxorubicine as first line therapy in stade III-IV ovarian carcinoma : results of an Artac phase III trial (meeting abstract). Proc Am Soc Clin Oncol 1992 ; 11 : 722a.
13. 13. Edmonson JH, McCormack GM, Wieand HS, Kugler JW, Krook JE, Stanhope CR, et al. Cyslophosphamide-cisplatin versus cyclophosphamide-carboplarin in srage III-IV ovarian carcinoma : a comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989 ; 81 : 1500-4.
14. 14. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage : prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 ; 7 : 1748-56.
15. 15. Vincent P, Kheder R, Glaisner S, Le Rol A, Malaurie E, Nation S, et al. Optimal carboplatin (CBDCA) dosage calculation when combined with paclitaxel (P) : a randomized trial of AUC vs BSA in patients (pts) with relapsed ovarian cancer (OG). Proc Am Soc Clin Oncol 1999 ; 771a.
16. 16. Chatelut E, Canal P, Brunner V, Chevreau G, Pujol A, Boneu A, et al. Prediction of carhoplatin clearance from standard morphological and biological parient characteristics. J Natl Cancer Inst 1995 ; 87 : 573-80.
17. 17. Bookman MA, McGuire WP, Kilpatrick H, Keenan F., Johnson S, O'Dwyer P, et al. Phase-I gynecologic oncology group (GOG) study of 3-H and 24 H paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995 ; 755a.
18. 18. Du Bois A, Lueck HJ, Meier W, Moebus V, Costa SD, Bauknecht T, et al. Cisplatin/paclitaxel in ovarian cancer : update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol 1999 ; 1374a.
19. 19. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (Carbo)/PAC in optimal stage III epithelial ovarian cancer (OC). A Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999 ; 1373a.
20. 20. Peter Harper on behalf of the ICON Collaborators. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agenr carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin) : 2 075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Cancer Division, MRC Clinical Trials Unit, Cambridge, UK, Proc Am Soc Clin Oncol 1999 ; 1375a.
21. 21. Anonymous. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma : a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991 ; 9 : 1668-74.
22. 22. Fanning J, et al. Metaanalysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet & Gynecol 1992 ; 15 : 129-34.
23. 23. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995 ; 45 : 726-32.
24. 24. Homesle HD, et al. Randomized comparison of cisplarin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. Am J Clin Oncol 1992 ; 15 : 129-34.
25. 25. Pfisterer J, Weber B, Du Bois A, Goupil A, Meier W, Mousseau M, et al. Ovarian Cancer Study Group. Kiel, Germany and Gineco Ovarian Cancer Study Group, France. Proc Am Soc Clin Oncol 1999 ; 1418a.
26. 26. Muggia F, Hainsworth J, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer : antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997 ; 15 : 987-93.
27. 27. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987 ; 5 : 756-67.
28. 28. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992 ; 10 : 520-8.
29. 29. Ngan HY, Choo YC, Cheung M, Wong LC, Ma HK, Collins R, et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 1989 ; 35 : 221-7.
30. 30. Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M, et al. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 1993 ; 4 : 377-83.
31. 31. Bella M, Cocconi G, Lottici R, Leonardi F, Ceci G, Passalacqua R, et al. Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann Oncol 1994 ; 5 (suppl. 8) : 2.
32. 32. Ben-David Y, Rosen B, Franssen E, Einarson T, Szyfer I. Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol 1995 ; 59 : 93-101.
33. 33. Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, et al. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma : en Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1991 ; 9 : 1793-800.
34. 34. Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries F, Kains JP, et al. Cisplatin combined with carboplatin : a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma. J Natl Cancer Inst 1990 ; 82 : 703-7.
35. 35. Fanning J, Hilgers RD. High dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 1993 ; 51 : 182-6.
36. 36. Heron JF, Kerbrat P, Mayer F, Chevallier B, Goupil A, Vennin P, et al. Cisplatin (cddp), carboplatin (cbdca) and cyclophosphamide (cpm) as first-line chemotherapy in advanced ovarian carcinoma (stage III-IV) with bulky residual disease (meeting abstract). Proc Am Soc Clin Oncol 1992 ; 705a.
37. 37. Michel G, Castaigne D, Morice P, Lhommé C, Dumillard P. La chirurgie supraradicale des cancers de l'ovaire avancés. (stades III et IV). Jobgyn juin 1997 ; 5-11.
38. 38. Van Der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995 ; 332 : 629-34.
39. 39. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993 ; 11 : 166-72.
40. 40. Dieras V, Ferrero JM, Kheder R, et al. Cisplatin-docetaxel (Taxotère®) in first line treatment of advanced ovarian cancer (AOC). Eur J Cancer 35 : p. S243, abstract 960.
41. 41. Misset JL, Chollet P, Vennin P, et al. Multicentric phase II-III trial of oxaliplatin (LOHP) versus cisplatin both in association with cyclophosphamide in the treatment of advanced ovarian cancer. Proc Am Soc Clin Oncol 1997 ; 1266.
42. 42. Ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan venus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 ; 15 : 2183-93.
43. 43. Hoskins P, Eisenhauer E, Fisher B, Vergote I, Dubuc J, Stuart G, et al. Sequential couplets of cisplatin (DDP)/topotecan (TOP) and cisplatin/paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer (EOC) : an NCIC clinical trials group phase II study. Proc Am Soc Clin Oncol 1999 ; 1378a.
44. 44. Gordon AN, Doherty M, Hancock KC, Messing M, Matthews CM, Teneriello M, et al. Phase I study of topotecan (T) with carboplatin (C) alternating with paclitaxel (P) via 3 hour infusion in combination with carboplatin (C) in treatment of newly diagnosed ovarian cancer (OC) Patients. Proc Am Soc Clin Oncol 1999 ; 1408a.
45. 45. Hansen SW, Anderson H, Boman K, Hansen M, Havsteen H, Rosenberg P, et al. Gemcitabine, carboplatin and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999 ; 1379a.
46. 46. Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Kavanagh JJ, Morris M, et al. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: « maintenance » therapy reconsidered. Gynecol Oncol 1992 ; 47 : 7-13.
47. 47. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992 ; 45 : 284-9.
48. 48. Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer : a Danish Ovarian Study Group trial (Dacova). Gynecol Oncol 1993 ; 49 : 30-6.
49. 49. Lambert H, Rustin G, Nelstrop A, Gregory WA. A randomised trial of 5 versus 8 courses of cisplatin or carboplatin in advanced ovarian carcinoma, (abstract 140). 5th biennail meeting of the International Gynecologic Cancer Society, September 4-8 Philadelphia, USA, 1995 ; 5 : 41.
50. 50. Piver MS, Lele SB, Marchetti DL, Baker TR, Emrich LJ, Hartman AB. Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 1988 ; 6 : 1679-84.
51. 51. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young J, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) VS IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer : a SWOG-GOG-ECOG intergroup study (INT 0051). Proc Am Soc Clin Oncol 1995 ; 760.
52. 52. Cain JM, Ellis GK, Collins C, Greer BE, Tamimi HK, Figge DC, et al. Bone marrow involvement in epithelial ovarian cancer by immunocytotechnical assessment. Gynecol Oncol 1990 ; 38 : 442-5.
53. 53. Curé H, Extra JM, Viens P, Lotz JP, Guastalla JP, Dieras V, et al. High-dose chemotherapy with hematopoietic stem cell support as consolidation therapy for patients with platinum-sensitive advanced eptithelial ovarian cancer. Bone Marrow Transplant 1998 ; 22 (suppl. 3) : S102-4.
54. 54. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescues in patients with stage III to IV ovarian cancer : long term results. J Clin Oncol 1997 ; 15 : 1302-8.
55. 55. Viens P, Maraninchi D, Legros M, et al. High-dose melphalan and autologous marrrow rescue in advanced epithelial ovarian carcinomas. Bone Marrow Transplant 1990 ; 5 : 227-33.
56. 56. Extra JM, Curé H, Viens P, et al. High-dose chemotherapy with autologous bone marrow transplantation in ovarian adeno-carcinoma. Bull Cancer 1993 ; 80 : 156-62.
57. 57. Pujade-Lauraine E, Guastalla JP, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparoromy. J Clin Oncol 1996 ; 14 : 343-50.
58. 58. Gotlies WH, Abrams JS, Watson JM, et al. Presence of interleukine 10 (IL10) in the of patients with ovarian and other intra-abdominal cancers. Cytokine 1992 ; 4 : 385-90.
59. 59. Goldman M, Velu T. L'interleukine 10, une nouvelle cytokine immunosuppresseuse et anti-inflammatoire. Medecine/Sciences 1993 ; 9 : 453-5.
60. 60. Faradji A, Bohbot A, Frost H, et al. Phase I study of liposomal MTP-PE activated autologous monocytes administered intraperitoneally to patients wih peritoneal carcinomatosis. J Clin Oncol 1991 ; 9 : 1251-60.